Is Bristol Myers stock undervalued?

According to the analysis, BMY trades at lower earnings multiples, suggesting a discounted valuation relative to peers.

What makes Johnson & Johnson a stable investment?

JNJ has industry-leading margins and cash flow, along with diversified operations across pharmaceuticals, medical devices, and consumer products.

Which stock is better for growth investors?

BMY may be more suitable for growth investors due to its discounted valuation and specialty drug focus, but it carries higher risk.

Bristol Myers vs. Johnson & Johnson: Which Healthcare Stock to Buy in 2026?

Investors eyeing healthcare stocks in 2026 weigh Bristol Myers Squibb (BMY) with its discounted valuation and focus on specialty medicines against Johnson & Johnson (JNJ), which boasts industry-leading margins and cash flow.

June 26, 2026

2 min read

Source: Motley Fool

As investors look for opportunities in the healthcare sector in 2026, two major names emerge: Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ). According to an analysis by Motley Fool, each offers distinct advantages.

Key Strengths

Bristol Myers Squibb (BMY)

Discounted Valuation: The stock trades at lower earnings multiples compared to peers, potentially offering value for investors.
Specialty Medicines Focus: BMY has a strong portfolio of specialty drugs, particularly in oncology and immunology.

Johnson & Johnson (JNJ)

Industry-Leading Margins and Cash Flow: JNJ boasts high profit margins and robust cash flow, reflecting its financial stability.
Diversification: Its operations span pharmaceuticals, medical devices, and consumer products, reducing risk.

What This Means for Investors

The choice between the two depends on investor style. If you seek value and lower valuation with higher risk, BMY may be suitable. If you prefer stability and strong cash flows, JNJ could be the better pick. It is advisable to conduct further research and consider your investment goals before making a decision.

Frequently Asked Questions

Bristol Myers focuses on specialty drugs with a discounted valuation, while Johnson & Johnson boasts strong margins and cash flow.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.